Introduction {#s0005}
============

Pancreatic cancer is one of the few cancer types where the 5-year survival rate shows no improvement [@bb0005]. In 2016 in the United States, pancreatic cancer was diagnosed in approximately 53,070 patients and caused an estimated 41,780 deaths [@bb0010]. In China, the incidence of pancreatic cancer was in an upward trend from 2000 to 2011, and pancreatic cancer is one of the top 10 most common cancers in both men and women [@bb0015]. In Europe, pancreatic cancer is currently one of the most lethal types of cancer and has a 5-year survival of approximately 7% [@bb0010]. It is expected to rise to second place behind lung cancer by 2030 [@bb0020]. Surgery is currently the only potentially curative treatment for pancreatic cancer [@bb0025]. However, pancreatic surgery in early state is associated with significant morbidity and mortality [@bb0030]. The poor prognosis of pancreatic cancer is mainly attributed to rapid disease progression; late diagnosis at advanced, unresectable stages; and inadequate response to current adjuvant or palliative regimens. Indeed, there is no effective diagnostic method at early stage, and most pancreatic cancer patients are first diagnosed at advanced stages [@bb0035], [@bb0040].

High-throughput technologies combined with vast amounts of publicly available data and sophisticated online analysis tools enable the scientific community to mine knowledge about genes related to cancer development in an unprecedented manner. Different types of molecular biomarkers can be used for diagnosis, prognosis, and prediction and monitoring of response to treatment. For example, the presence or absence or changes in the level of specific biomarkers in a cell are routinely used as an indication of cancer development. Molecular biomarkers are an important diagnosis tool in pancreatic cancer [@bb0045]. Thus, multiple studies have confirmed that carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) can be used to predict the outcomes of multiple diseases, including pancreatic cancer [@bb0050], [@bb0055], [@bb0060]. However, these biomarkers are not sufficiently specific or sensitive for use in pancreatic cancer [@bb0065], [@bb0070]. The identification of novel pancreatic cancer-specific molecular biomarkers is crucial for early effective diagnosis [@bb0075].

Microarrays, including DNA, microRNA, protein, and antibody microarrays, are a multiplex lab-on-a-chip system. More specifically, a microarray is a 2D array on a solid substrate for assaying large amounts of biological material using miniaturized, multiplexed, and parallel processing and detection methods. Microarrays are widely used in biomedical research. For instance, they have been used to infer general genetic alterations during tumorigenesis [@bb0080]. Microarray data are also the main resources of biomarker candidates [@bb0085]. In this study, we integrated data from three mRNA microarray datasets and a microRNA dataset with pathway, functional, and overall survival analysis to identify putative novel pancreatic cancer biomarkers among differentially expressed genes (DEGs) and microRNAs (DEMs) between normal and pancreatic cancer tissue. Crispr Cas9 system has led a revolution in gene editing. Our laboratory has done a lot of work on this field with wealth of experience. In this study, we verified the data mining results by Crispr Cas9 gene editing system and other experiments.

Materials and Methods {#s0010}
=====================

Microarray Datasets and Data Processing {#s0015}
---------------------------------------

We selected and downloaded three human pancreatic cancer gene expression (GSE16515 [@bb0090], GSE15471 [@bb0095], and GSE28735 [@bb0100], [@bb0105]) and one human pancreatic cancer miRNA expression (GSE41372 [@bb0110]) datasets from the Expression Omnibus database (GEO) [@bb0115]. The three gene expression datasets include 117 cancer tissue samples and 97 normal tissue samples from 117 pancreatic cancer patients. The miRNA dataset comprises pancreatic ductal adenocarcinoma tumor samples from nine patients and normal pancreas samples from nine healthy individuals. All these datasets were generated on Affymetrix chips and uploaded by independent groups. The GSE16515 and GSE15471 datasets are based on the GPL570 platform; the GSE28735 and GSE41372 datasets are based on the GPL16142 platform. These platforms are the mainstream choice for biomarker research [@bb0120].

We used GEO2R [@bb0125] to identify DEGs and DEMs between pancreatic cancer and normal tissue samples. GEO2R is an online tool which can compare different groups in a GEO series. The pancreatic cancer samples served as the "cancer group," and the normal samples as the "control group." We selected genes whose adjusted (Benjamini & Hochberg or false discovery rate [@bb0130]) *P* value was smaller than .01 and with an absolute log fold-change greater than 1.

We used the online tool "Calculate and draw custom Venn diagrams" ([http://bioinformatics.psb.ugent.be/webtools/Venn/](http://bioinformatics.psb.ugent.be/webtools/Venn){#ir0005}) to identify genes that were up- or downregulated in all three GEO datasets.

Gene Function and Pathway Enrichment Analysis {#s0020}
---------------------------------------------

We used the Database for Annotation, Visualization, and Integrated Discovery (DAVID [@bb0135]) to perform a functional enrichment analysis of the DEGs. DAVID is an online program to help understand biological meaning behind plenty of genes with comprehensive function, including the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. We set the cutoff criterion *P* \< .05 of false discovery rate.

Protein-Protein Interaction (PPI) Network Construction and Module Analysis {#s0025}
--------------------------------------------------------------------------

We used the Search Tool for the Retrieval of Interacting Genes (STRING) database to analyze functional interactions between proteins [@bb0140]. We retrieved interactions with confidence scores greater or equal to 0.7 and screened the resulting PPI network for modules with Cytoscape-MCODE [@bb0145] and the following parameters: degree cutoff=2, node score cutoff=0.2, k-core=0.2, and maximum depth=100.

Prediction of miRNA Targets {#s0030}
---------------------------

We used GEO2R to identify DEMs between pancreatic cancer and normal tissue samples. The pancreatic cancer samples served as the "cancer group" and the normal samples as the "control group." We selected miRNAs whose adjusted (Benjamini & Hochberg or false discovery rate [@bb0130]) *P* value was smaller than .01 and with an absolute log fold-change greater than 1. We used the "miRecords" tool to predict miRNA target genes [@bb0150]. miRecords integrates the results of more than 10 miRNA target prediction programs. No target was predicted for more than six miRNA target prediction programs, so we only considered DEM target genes predicted by exactly six prediction programs. Finally, we used the online tool "Calculate and draw custom Venn diagrams" ([http://bioinformatics.psb.ugent.be/webtools/Venn/](http://bioinformatics.psb.ugent.be/webtools/Venn){#ir0010}) to identify common target DEGs of for the DEMs.

Survival Analysis of DEGs {#s0035}
-------------------------

We used the OncoLnc tool ([www.oncolnc.org](http://www.oncolnc.org){#ir0015}) [@bb0155] to perform overall survival analysis in pancreatic cancer. OncoLnc is an online tool for interactively exploring survival correlations. It contains survival data for 8647 patients from 21 cancer studies in The Cancer Genome Atlas (TCGA), along with RNA-seq data for mRNA and miRNA expression from TCGA, and lncRNA expression from MiTranscriptome beta. The tool gives the user the ability to separate patients based on the gene expression level of a specific gene and create Kaplan-Meier plots. We recorded hazard ratios with their 95% confidence intervals and log-rank *P* values. Top 10, 20, and 40 and bottom 90, 80, and 60 percentiles of expression values, respectively, were considered as high and low groups. Additionally, OncoLnc was used to do the overall survival analysis for other cancer types, including breast, lung, gastric, and liver cancer.

The Basic Expression of DEGs in Different Organs and Cancer Tissues {#s0040}
-------------------------------------------------------------------

We used the online tool " The Human Protein Atlas " to perform the basic expression level of DEGs in different human organs. The Human Protein Atlas is a Swedish-based program started in 2003. We worked with version 17 in this study, which was launched in August 2017 [@bb0160]. In the Tissue Atlas part, it shows the distribution of the proteins across all major tissues and organs in human. There were three datasets in the website: HPA dataset (RNA-seq tissue data are reported as mean transcripts per million, corresponding to mean values of the different individual samples from each tissue), GTEx dataset (RNA-seq data are reported as median reads per kilobase per million mapped reads, generated by the Genotype-Tissue Expression project), and FANTOM5 dataset (tissue data obtained through cap analysis of gene expression are reported as tags per million, generated by the FANTOM5 project). We used them together in this study. In additional, we also conducted the different expression between normal pancreas and pancreatic cancer tissues. UALCAN is an easy-to-use online tool for in-depth analyses of TCGA gene expression data. It uses TCGA level 3 RNA-seq and clinical data from 31 cancer types. In this study, we used it to identify the up- or downregulated of DEGs in pancreatic cancer.

Cell Culture {#s0045}
------------

In this study, we used human pancreatic cancer lines ASPC1, BXPC3, PANC1, HS766T, and MiaPaCa 2; primary cell lines PaCaDD119, PaCaDD137, and PaCaDD159; and normal pancreas cell line HDPE. ASPC1, BXPC3, PANC1, HS766T, MiaPaCa 2, and HDPE were purchased from ATCC, and all the cells were grown in monolayer culture in a humidified atmosphere containing 5% CO2 at 37°C. The culture medium for ASPC1, BXPC3, and PANC1 consists of RPMI Medium 1640 (Gibco, 21875-034) with 10% FBS (Gibco, A31608-01). HS766T cell was cultured in DMEM (Gibco, 30966-021) with 10% FBS. MiaPaCa 2 cell was cultured in DMEM with 10% FBS and 2% horse serum (Gibco, 16050-130). HDPE cell was cultured in Keratinocyte-SFM (Gibco, 10724-011). PaCaDD119, PaCaDD137, and PaCaDD159 were cultured in mixed medium with 53.5% DMEM, 13.2% FBS, and 33.3% Keratinocyte-SFM. All cells were harvested by 0.25% Trypsin-EDTA (Gibco, 25200-072).

Western Blot {#s0050}
------------

Cells were lysed with RIPA buffer. Gel electrophoresis was performed under reducing conditions with acrylamide gel, and proteins were transferred to a nitrocellulose membrane. As primary antibodies, ECT2 (Merck Millipore, 07-1364), NRP2 (Cell Signaling Technology, 3366), and TGFBI (Thermo Fisher Scientific, PA5-19242) were used for detection. The GAPDH (Cell Signaling Technology, 5175S) served as loading control. HRP-linked anti-rabbit IgG (Cell Signaling Technology, 7074) was used as second antibody. Quantification of signal was performed by Amersham Imager 600 with SignalFire Elite ECL Reagent (Cell Signaling Technology, 12757S). All Western blot results were done at least two times.

Quantitative RT-PCR {#s0055}
-------------------

The isolation of RNA was performed with NucleoSpin RNA Plus kit (Macherey-Nagel, \#740984.250), and the cDNA was synthesized with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 00364942). The quantitative RT-PCR was performed with PowerUP SYBR Green Master Mix (Applied Biosystems, A25741) and analyzed by 2^−△△Ct^ method. The GAPDH was used as reference value. Primer sequences for amplification were as follows: ECT2-forward (5′- AGGAGTCGGCGTTTGAAGAG-3′), ECT2-reverse (5′- GGTCCAATAACTCTACAATCAGCC-3′), NRP2-forward (5′- CGCGGAGGAGACAGTATCAC-3′), NRP2-reverse(5′- CCGAAGAGGAGGCCACAGAG-3′), TGFBI-forward (5′- AAGGTAACGGCCAGTACACG-3′), TGFBI-reverse(5′- GAGATGATCGCCTTCCCGTT-3′), GAPDH-forward (5′-CTTTGGTATCGTGGAAGGACTC-3′), GAPDH-reverse(5′-AGTAGAGGCAGGGATGATGT-3′). All primers were synthesized by Eurofins.

CRISPR/Cas9 Gene Editing {#s0060}
------------------------

In this study, ECT2 was knocked out by CRISPR/Cas9 gene editing in the MiaPaCa2 cell line. The pSpCas9(BB)-2A-GFP (PX458, Plasmid \#48138) plasmid was purchase from Addgene. HGLibB-14402-ECT2 sgRNA (forward: 5′- CACCTGTCTTTAATGACCTCTACA -3′ and reverse: 5′-AAACTGTAGAGGTCATTAAAGACA-3′) and Hu-64433nc-sgRNA (forward: 5′-CACCATCGTATCATCAGCTAGCGC-3′ and reverse: 5′-AAACGCGCTAGCTGATGATACGAT-3′) were synthesized by Eurofins. Plasmid construction was done as described in the protocol and confirmed by sequencing. MiaPaCa cells were transfected with ECT2 knockout plasmid by Lipofectamine 3000 Transfection Reagent (Invitrogen, L3000015) as protocol for 72 hours. Then, all the GFP-positive cells were sorted by fluorescence activated cell sorter. Sixty GFP-positive cells were plated in one 96-well plate for selecting single clones. After a few days of culture, Western blot and sequencing were used to make sure the knockout effect. Sequencing was done by Eurofins, and all selected clones were sequenced at least five times.

Proliferation Assay {#s0065}
-------------------

Cell counting was used to analyze the proliferation ability between ECT2 knockout clones and negative control clone. Cells were plated as 3 × 10^3^ cells per well in grown medium on 96-well black plates (Costar, \#3603) for 4 days. After 24, 48, and 72 hours of proliferation, cells were stained with NucBlue Live Cell Stain ReadyProbes reagent ( Invitrogen, R37605) and imaged in 38 fields for each well by Evos FL Auto 2 imaging system (Invitrogen, AMAFD2000). Images were counted by HCS studio cell analysis software (Thermo, SX000041A). All experiments were done in duplicate and repeated at least three times.

Migration Assay {#s0070}
---------------

FluoroBlok Insert system (Corning, REF351152) was used to analyze the migration ability between ECT2 knockout clones and negative control clone. After incubation with medium without FCS for 24 hours cells were plated as 25,000 cells per well in FluoroBlokTM Insert, and put FluoroBlokTM Insert into Multiwell 24 Well (Corning, REF353504). The medium in the upper compartment was without FCS, in the lower compartment the growth medium contained 20% FCS. After 16 hours of migration in a cell culture incubator, the NucSpot Live 488 Nuclear Stain (Biotium, Cat40081) was used, and the cells attached on center of the membrane were imaged in random four fields for each well by Evos FL Auto 2 imaging system (Invitrogen, AMAFD2000).The positive point in all images was manually counted.

Statistical Analysis {#s0075}
--------------------

Statistical analysis was performed with GraphPad Version 7 and Microsoft Excel Version 2017. For cell culture experiments, *t* test was used. For interpretation of differences, a *P* value \< .05 was considered as statistically significant.

Results {#s0080}
=======

Identification of DEGs in Gene Expression Microarrays {#s0085}
-----------------------------------------------------

We identified 1647, 1693, and 407 DEGs in pancreatic cancer tissue compared to normal tissue in the GSE15471, GSE16515, and GSE28735 datasets, respectively. A total of 236 genes were considered DEG in all the 3 datasets ([Figure 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}, see Materials and Methods). In particular, 182 genes were upregulated and 54 genes were downregulated.Figure 1Identification of DEGs in mRNA expression profiling datasets GSE15471, GSE16515, and GSE28735. (A) The upregulated genes in the profiling datasets. (B) The downregulated genes in the profiling datasets.Figure 1Table 1Total 236 Genes Which Showed Consistent Trend in Up- or Downregulation in Three Microarrays Were Considered DEG in GSE15471, GSE16515, and GSE28735 DatasetsTable 1Upregulated DEGsGSE15471GSE16515GSE28735Adj *P*Log FCAdj *P*Log FCAdj *P*Log FCABHD17C6.41e-05−1.105627341.60e-08−2.8958253.31e-12−1.128362ACSL52.43e-03−1.183565391.96e-04−1.92449098.95e-08−1.4634847ACTA29.91e-06−1.563473114.02e-03−1.35216141.73e-05−1.1454927ADAM124.08e-08−1.815739182.20e-02−1.21556626.89e-04−1.0717007ADAM281.00e-07−1.861731773.35e-04−1.59779785.10e-06−1.141082ADAM92.19e-10−1.711064728.41e-07−1.84661361.74e-07−1.1530387ADAMTS125.56e-17−2.420532662.20e-04−1.86831583.77e-09−1.4163264ADAMTS61.14e-08−1.086452672.58e-05−1.19854812.89e-08−1.038462ADGRF14.41e-06−1.139785832.11e-03−1.18935991.24e-08−1.6035156AEBP12.36e-16−2.707164381.99e-03−1.71542451.80e-06−1.1198558AGR21.28e-04−2.049644133.29e-05−2.77219822.25e-10−2.1373789AHNAK22.75e-13−2.539761842.20e-04−1.63469645.51e-13−1.7455516ANKRD221.07e-05−1.308589932.94e-07−2.11285291.35e-08−1.5765009ANLN4.03e-06−1.30953821.35e-07−2.2315187.00e-09−1.6620173ANO16.05e-15−2.970531761.59e-04−1.75742922.55e-09−1.2739089ANTXR11.83e-12−1.490815398.76e-04−1.2185397.64e-09−1.5904338ANXA109.12e-05−2.007051042.49e-04−3.25098517.58e-09−2.3579367ANXA32.08e-07−1.492080351.47e-06−1.93014694.51e-06−1.0462073ANXA8L1///ANXA81.24e-05−1.290987071.50e-04−2.85780111.45e-07−1.4583824APOL12.98e-10−1.118567611.82e-06−1.94697037.27e-10−1.5050227AREG2.33e-06−1.955747582.20e-04−1.98266713.11e-03−1.0105213ARNTL21.55e-09−1.438393671.05e-06−1.84534651.15e-08−1.2634424ASAP25.40e-12−1.271420481.25e-06−1.44371811.38e-11−1.0555331ASPM1.34e-05−1.383131054.95e-06−2.16642532.91e-07−1.2180584BGN2.63e-12−1.617020334.83e-03−1.29801395.11e-06−1.2178456CAPG1.74e-16−2.230184368.56e-06−2.22904118.56e-10−1.409224CCL184.24e-05−1.500086423.09e-03−1.78690041.20e-03−1.1312298CCL202.65e-06−2.188363119.93e-06−3.34828983.16e-08−1.3648089CD1097.32e-12−2.358110141.96e-04−1.95080992.18e-07−1.2498704CDH112.09e-11−1.622274238.02e-04−1.20808042.35e-07−1.4890444CDH34.98e-09−1.501295247.33e-07−2.68258561.81e-12−1.6362931CEACAM14.36e-05−1.416218392.67e-06−1.6357773.37e-09−1.292694CEACAM57.46e-06−2.765268482.33e-07−6.25256631.07e-10−3.1812869CEACAM63.73e-08−3.198758532.11e-06−4.26002633.78e-10−2.6271224CEMIP2.81e-07−2.458968574.01e-06−2.78463019.49e-11−1.8033796CLDN182.91e-04−1.610763892.73e-05−4.03648722.41e-08−2.1265416COL10A14.79e-18−4.114432231.37e-05−3.36735232.59e-11−1.5692449COL11A11.24e-07−1.881136671.64e-04−2.25895121.42e-10−2.1946749COL12A17.24e-08−1.524347853.78e-04−1.62683383.71e-07−1.732026COL1A18.67e-08−1.335044181.18e-03−2.09145041.80e-05−1.5020929COL3A15.36e-10−1.476895892.61e-03−1.27761557.92e-05−1.3701904COL5A24.21e-16−3.444229327.75e-04−1.86673158.85e-06−1.3867727COL8A11.60e-14−2.086599481.46e-02−1.05325592.56e-07−1.4414827COMP1.60e-14−3.574539983.99e-03−2.1558562.08e-06−1.4673376CORIN6.57e-09−1.800419169.81e-04−1.49096157.13e-07−1.0800867CP3.17e-05−1.381834292.07e-02−1.35312843.29e-05−1.767232CST14.28e-13−3.346476554.61e-04−3.03828252.25e-08−2.0248356CST24.08e-10−1.802133422.41e-03−1.24891289.70e-09−1.2321847CTHRC16.72e-17−4.430753842.67e-04−2.73088797.77e-09−1.0049256CTSE3.35e-08−2.72577672.67e-07−4.62086796.93e-12−2.6841011CTSK2.95e-13−2.614239677.83e-03−1.39866922.43e-04−1.0460687CXCL57.79e-08−2.42559661.03e-04−3.66100981.74e-07−1.5615738DCBLD21.10e-09−1.340565873.01e-03−1.1116353.46e-07−1.0321687DDX602.29e-08−1.557034813.20e-05−1.54696026.06e-07−1.0535862DGKH5.53e-09−1.516583172.00e-04−1.30506337.09e-07−1.0501716DHRS91.83e-07−1.251234275.22e-04−2.43395742.72e-06−1.2735449DKK13.90e-10−2.306617261.03e-06−3.87619452.17e-07−1.2162724DLGAP51.41e-04−1.036192367.33e-07−2.07904016.75e-07−1.1127349DPCR12.17e-03−1.164531638.01e-05−3.72338795.55e-08−2.1386271DPYSL38.50e-12−2.017013064.72e-03−1.39995872.12e-05−1.1362667ECT22.12e-10−2.183673541.04e-04−1.20245234.55e-10−1.3293738EDIL33.14e-11−2.559470481.10e-03−1.54766788.64e-07−1.5138422EDNRA1.24e-14−1.838214051.84e-03−1.35562562.52e-07−1.3127658EFNA51.66e-10−1.357824036.99e-06−1.30283347.69e-10−1.1553482EFNB21.18e-07−1.327431053.28e-05−2.0380122.49e-09−1.0293451ENO25.56e-10−1.61297829.21e-05−1.69467011.25e-07−1.1134007EPHA41.75e-08−1.017583542.29e-03−1.07611631.88e-07−1.1711916EPYC1.32e-04−1.732761748.42e-03−1.93659659.64e-04−1.0430022ERO1A1.11e-05−1.05603888.59e-07−1.92375511.17e-09−1.219264ETV19.65e-14−2.30344633.70e-04−1.2701312.53e-06−1.0579796FAP1.77e-16−3.388810492.81e-03−1.90464041.33e-05−1.4972633FBXO329.65e-14−1.723595722.45e-03−1.38356392.13e-11−1.4711818FCGR3B///FCGR3A7.76e-08−2.416748266.89e-03−1.64251056.57e-05−1.0251151FERMT11.64e-06−1.353061114.34e-06−1.37727767.21e-10−1.5010753FGD61.59e-09−1.061241452.87e-07−1.61014247.37e-10−1.2339911FN12.54e-10−1.508890452.98e-03−1.47483148.61e-10−2.2111FNDC12.35e-13−2.726292228.25e-03−1.63307361.79e-06−1.4763207FOXQ11.99e-07−1.956399522.26e-07−2.59485725.81e-09−1.1159918FXYD39.25e-07−1.800336982.60e-06−2.07438899.49e-11−1.5452418GABRP4.28e-09−3.018179451.64e-04−3.62085162.95e-06−2.0308344GCNT35.28e-05−1.847821011.03e-06−3.35471333.12e-06−1.4315447GJB23.55e-13−3.691099581.68e-07−3.58614892.21e-12−1.0717644GPRC5A1.73e-13−2.710730282.33e-07−3.77771467.88e-10−1.1751238GPX26.17e-06−2.067534797.71e-03−1.05708481.44e-05−1.1878256GPX86.62e-13−1.753194594.07e-03−1.07461345.69e-06−1.0094489GREM18.23e-09−3.206685561.89e-03−2.00677142.56e-07−1.0603713HEPH1.09e-06−2.049894369.21e-04−2.17882152.74e-07−1.2034709HK27.54e-10−1.549615141.25e-08−2.71613197.91e-09−1.3526864IFI271.87e-09−2.242776822.33e-07−3.32958333.18e-09−1.3512633IFI44L9.20e-10−1.997373281.04e-03−2.05397911.51e-04−1.2289118IGF2BP31.63e-07−1.587463231.67e-05−3.05287051.76e-07−1.1658791IGFBP54.44e-10−1.002177991.31e-03−1.36274842.24e-05−1.3557069IL1R24.90e-07−1.653523883.00e-04−2.06179291.07e-06−1.0359142INPP4B2.09e-10−1.615252461.07e-03−1.40331335.46e-09−1.12227ITGA23.03e-12−1.381907671.13e-07−2.64910864.28e-11−2.2658244ITGA37.36e-09−1.328644721.25e-06−2.28004497.10e-10−1.5188551ITGB46.66e-09−1.233135952.66e-05−1.92591572.30e-11−1.303354KCNN41.15e-07−1.110848664.45e-07−2.24002051.59e-14−1.0487336KRT193.16e-11−3.710891111.61e-08−4.4729291.21e-11−2.0580204KRT71.31e-13−3.107304176.96e-07−3.28725885.98e-07−1.6835824KYNU3.47e-08−1.170461531.57e-04−1.38766351.61e-06−1.2622391LAMA34.56e-09−2.257961542.83e-03−1.37559938.50e-12−1.3547947LAMB31.58e-08−1.79451342.96e-10−3.67389911.59e-14−2.3442298LAMC23.83e-09−1.596284764.14e-07−3.09359741.59e-14−2.9016536LCN28.46e-09−2.890697356.50e-06−3.78675266.00e-05−1.1424984LEF12.24e-10−2.753427661.16e-04−2.48649916.33e-09−1.3104127LOXL21.75e-09−1.612160465.53e-06−2.29267831.28e-08−1.2380353LRRN12.66e-12−1.687458714.99e-04−1.54384673.21e-06−1.1022207MALL4.20e-05−1.441767334.37e-05−2.55839355.55e-08−1.0471758MBOAT21.30e-10−1.129726121.27e-06−1.90185491.76e-11−1.5977576MELK4.19e-06−1.211519881.50e-06−2.02705391.38e-07−1.1532836MET2.66e-09−1.502072366.50e-04−1.16835511.20e-09−1.4803842MICAL21.38e-10−1.203916226.07e-04−1.11883937.99e-11−1.2684082MLPH2.74e-07−1.477172384.75e-07−2.7480771.63e-14−1.4629327MMP12.56e-08−3.491480024.63e-04−2.96070881.36e-03−1.2251593MMP112.98e-09−1.961779831.92e-05−2.67229792.28e-09−1.5014524MMP122.52e-06−2.664354435.23e-04−3.11681242.42e-07−1.7443562MMP149.90e-11−1.198116736.29e-05−1.2224549.99e-09−1.325874MMP76.50e-11−3.371960748.22e-04−2.41861421.57e-03−1.2129338MMP97.76e-04−1.258410135.39e-04−1.74593012.83e-07−1.1166764MTMR112.59e-08−1.735785474.71e-06−2.39637929.96e-11−1.1160298MXRA56.59e-14−2.38762673.45e-04−1.79451931.56e-06−1.1398482MYOF1.50e-15−2.313805331.80e-05−1.54935166.87e-09−1.3488062NMU1.21e-07−1.7417117.71e-07−3.44244422.18e-08−1.0295189NOX44.79e-18−3.027670599.50e-05−2.31544532.09e-10−1.6264947NPR32.04e-08−1.425357056.59e-05−1.87970231.10e-06−1.2844418NQO11.99e-06−1.550218341.51e-07−2.87562531.46e-10−1.4664629NRP23.65e-09−1.001016637.92e-04−1.00367632.27e-07−1.0398169NT5E1.64e-05−1.575625932.94e-03−1.03295357.10e-06−1.208268OAS19.55e-07−1.217387024.37e-05−2.34348413.69e-08−1.130268OAS21.22e-07−1.390782447.96e-04−1.0639743.18e-07−1.0571731OLR11.05e-13−2.998890517.02e-04−2.23246361.91e-04−1.2763264OSBPL35.07e-09−1.438085191.23e-06−1.81040333.59e-08−1.1831684PCDH79.65e-07−1.228686492.91e-04−1.44547598.62e-10−1.0136969PGM2L19.65e-14−1.610203431.50e-04−1.40757553.30e-09−1.0538702PKM1.15e-12−1.534104631.49e-05−1.13325672.28e-09−1.021846PLA2R12.50e-08−1.202224472.37e-04−1.20002762.51e-07−1.1070027PLAC87.70e-04−1.699964624.67e-06−3.57918256.80e-08−1.8359027PLAT1.12e-11−2.539908574.05e-03−1.7573768.54e-07−1.3462227PLAU2.69e-11−2.050292474.78e-05−2.22173292.68e-08−1.3743673PLPP41.80e-11−2.22631662.18e-05−2.40513616.88e-12−1.1414518POSTN1.94e-07−1.333505611.09e-04−2.79026792.53e-10−2.6298373PXDN6.18e-07−1.368973533.37e-03−1.20992971.04e-05−1.1653407RAI142.21e-09−1.437406692.98e-05−1.25291261.57e-07−1.0131847RHBDL21.29e-07−1.175638067.96e-05−1.16282869.96e-11−1.1258644RUNX29.52e-11−2.928386518.05e-04−1.94776361.96e-10−1.2121193S100A161.59e-08−1.16509219.73e-08−2.1100293.77e-10−1.1656542S100P9.23e-11−3.666580894.81e-09−6.25801346.89e-14−1.2260793SCEL4.29e-06−1.265698082.44e-03−1.13553726.18e-11−1.6301907SCNN1A6.02e-04−1.088864971.59e-03−1.54642866.28e-06−1.0022056SDR16C57.10e-08−2.315200762.32e-08−4.18474443.80e-12−1.5155709SEMA3C7.54e-09−1.224264692.11e-03−1.65036234.02e-04−1.0999293SERPINB33.59e-05−1.60549874.16e-03−1.89530116.28e-04−1.2747167SERPINB51.31e-07−2.320540663.79e-08−4.3928441.21e-11−2.1830693SLC22A37.77e-06−1.097810141.34e-04−1.64632254.44e-06−1.14787SLC2A17.88e-08−1.414786832.96e-10−3.05335663.62e-12−1.8381029SLC44A41.94e-04−1.274537523.13e-05−2.39954529.50e-08−1.2232882SLC6A141.67e-09−3.009938949.65e-08−4.62658133.82e-12−3.075768SLC6A63.25e-14−2.681870197.62e-05−1.8253233.86e-08−1.2712856SLPI2.79e-14−2.674591321.24e-08−3.31294658.66e-09−1.7899024SRPX28.92e-16−2.472875999.36e-04−1.65445533.38e-05−1.1052856ST6GALNAC11.22e-03−1.361962241.41e-04−2.84121391.24e-07−1.028552STYK16.76e-06−1.253562624.62e-06−1.62943176.56e-13−1.2155107SULF11.31e-19−3.689405741.45e-04−2.41813961.52e-08−1.9594916SULF25.19e-10−2.106147386.89e-04−1.62461883.13e-05−1.0889349SULT1C22.42e-03−1.33037513.50e-03−1.77269364.11e-04−1.0128167SYTL22.17e-09−1.665328073.23e-04−1.76709931.40e-08−1.0928962TCN11.36e-07−2.900904041.95e-04−3.32908831.94e-04−1.5896369TFF11.06e-04−2.399096741.28e-05−4.68342844.87e-07−1.9432884TGFBI7.08e-10−1.893450654.10e-04−1.64600461.92e-06−1.1341551TGM25.08e-09−1.128333452.32e-03−1.78319112.70e-06−1.205276THBS21.26e-17−3.984579194.24e-04−2.1819012.56e-07−1.6264449TMC52.08e-04−1.276982461.10e-05−2.63880043.41e-07−1.7178244TMEM45B1.56e-03−1.40885819.04e-05−2.12791755.75e-07−1.3963273TMPRSS42.04e-07−1.96372761.14e-09−4.50413047.48e-13−2.2573618TNFAIP67.96e-11−2.487657911.06e-03−1.54056431.75e-04−1.30502TOP2A7.40e-06−1.489658627.55e-07−2.36406361.27e-07−1.3128398TRIM292.88e-10−2.000856538.29e-09−3.50360335.15e-11−1.4077371TSPAN11.16e-07−1.782939152.62e-08−3.68829711.63e-14−2.7266844TSPAN81.36e-02−1.30327922.05e-07−2.47828731.15e-04−1.4074942VCAN5.20e-17−3.737401939.41e-04−1.94616351.73e-06−1.7040513VSIG11.80e-05−1.78320751.95e-03−2.2006998.04e-08−1.9952567 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Functional and Pathway Enrichment Analysis {#s0090}
------------------------------------------

DAVID was used to analyze the functions and pathways (see Materials and Methods) of identified DEGs. DEGs were mainly involved in biological processes associated integrin-mediated signaling pathway, proteolysis, and collagen catabolic process. Moreover, seven KEGG pathways were overrepresented among upregulated genes, including ECM-receptor interaction, focal adhesion, and PI3K-Akt signaling pathway ([Table 2](#t0010){ref-type="table"}).Table 2Functional and Pathway Enrichment Analysis of Upregulated and Downregulated Genes in Pancreatic Cancer with the DEGs in the Three mRNA Expression Profiling DatasetsTable 2TermDescriptionCount*P* Value**Upregulated** GO:0030198integrin-mediated signaling pathway211.05E-14 GO:0030574collagen catabolic process146.69E-14 KEGG:hsa04512ECM-receptor interaction131.88E-10 GO:0004222metalloendopeptidase activity121.65E-08 GO:0030199collagen fibril organization81.17E-07 KEGG:hsa04510Focal adhesion144.69E-07 KEGG:hsa05146Amoebiasis102.82E-06 GO:0005201extracellular matrix structural constituent84.49E-06 GO:0004252serine-type endopeptidase activity139.59E-06 KEGG:hsa04151PI3K-Akt signaling pathway152.96E-05 GO:0005581collagen trimer83.05E-05 GO:0031581hemidesmosome assembly42.13E-04 KEGG:hsa04974protein digestion and absorption74.74E-04 GO:0007229integrin-mediated signaling pathway75.24E-04 GO:0005788endoplasmic reticulum lumen95.65E-04 GO:0006508proteolysis156.11E-04 GO:0007160cell-matrix adhesion60.00226 KEGG:hsa05222small cell lung cancer60.002763 KEGG:hsa05200Pathways in cancer120.004792 GO:0043588skin development40.004925 GO:0048333mesodermal cell differentiation30.005338**Downregulated** GO:0003756protein disulfide isomerase activity30.001837

PPI Network Construction and Modules Selection {#s0095}
----------------------------------------------

The PPI network (see Materials and Methods) included 182 upregulated (176 nodes and 282 edges) and 54 downregulated (52 nodes and 10 edges) DEGs ([Figure 2](#f0010){ref-type="fig"}*A*). A total of 12 genes, including THBS2and ITGA3, have more than 10 interaction partners ([Figure 2](#f0010){ref-type="fig"}*B*) and are potential hub genes. A significant module was observed in the PPI network of DEGs ([Figure 2](#f0010){ref-type="fig"}*B*). Overall survival analysis of the hub genes (see Materials and Methods) showed that the expression level of most of them (10/12) is strongly associated with the overall survival in pancreatic adenocarcinoma. In particular, low expression levels (bottom 10%) are associated with poor survival, while high expression levels (top 90%) are associated with improved survival ([Table 3](#t0015){ref-type="table"}, 10% vs 90% part). However, the effect decreases when patients are split into the bottom 20% and upper 80% and into the bottom 40% and upper 60% according to their expression values for the corresponding genes, with 5/12 and 4/12 hub genes showing a significant correlation with the overall survival, respectively ([Table 3](#t0015){ref-type="table"}, 20% vs 80% and 40% vs 60% part). (See [Fig. 3](#f0015){ref-type="fig"}.)Figure 2PPI network and a significant module. (A) PPI network of total DEGs in the three mRNA expression profiling datasets. (B) A significant module selected from PPI network. All the genes are upregulated genes. The line represents interaction relationship between nodes.Figure 2Table 3Significant Prognostic Value of Hub Genes and Screening Out DEGs in Pancreatic Cancer PatientsTable 310% vs 90%Gene nameCOMPFN1ITGB4COL8A1COL10A1Log-rank *P* value.0193.0301.000194.00444.00158Gene nameCOL5A2ITGA2ITGA3THBS2COL3A1Log-rank *P* value.00416.0309.0252.0207.00386Gene nameECT2NRP2TGFBILog-rank *P* value.00124.0177.0199  20% vs 80%Gene nameITGB4COL11A1ITGA2ITGA3THBS2Log-rank *P* value.000842.0241.0152.000484.00866Gene nameECT2NRP2TGFBILog-rank *P* value.00484.00801.0448  40% vs 60%Gene nameITGB4COL11A1ITGA2ITGA3Log-rank *P* value.00836.01132.91e-066.21e-05Gene nameECT2NRP2TGFBILog-rank *P* value.000851.059.0343Figure 3Identification of DEGs and paired miRNAs in the three mRNA expression and one miRNA expression profiling datasets. We found four specially DEGs and their miRNA, including ECT2-miR302c, NR5A2-miR27a, NRP2-miR27a, and miR331-3p, TGFBI-miR21.Figure 3

MiRNA-DEG Pairs {#s0100}
---------------

We identified 21 DEMs in pancreatic cancer tissue compared to normal tissue in the GSE41372 dataset. In particular, 19 miRNAs were upregulated and 2 were downregulated ([Table 4](#t0020){ref-type="table"}). Using miRecords (see Materials and Methods), we predicted 718 gene targets for these DEMs. Specifically, four predicted DEM targets were DEGs: NRP2 was among the predicted gene targets of miR27a, and miR331-3p, ECT2, NR5A2, and TGFBI were among the predicted gene targets of miR302c, miR27a, and miR21, respectively.Table 4DEMs in Pancreatic Cancer Screened Out from miRNA Expression Microarray GSE41372 and Their Target Genes Predicted by miRecordsTable 4miRNAAdj.PlogFCTarget Geneshsa-miR-6300.002038−4.21846NAhsa-miR-302c0.002434−1.37368E2F7, PARP8, NEUROD6, SLC22A23, CFL2, DMTF1, TNFAIP1, ZNFX1, TSHZ3, DCUN1D1hsa-miR-337-3p0.0039221.307959NAhsa-miR-190b0.0057681.369034NAhsa-miR-140-3p0.0036381.504247NAhsa-miR-331-3p0.0034971.830589B4GALT2, ZNF513, RIC8B, BAIAP2, CPSF2, CAMK2A, SNX17, PHC2, DAG1, NRP2hsa-miR-4840.0020381.835517NAhsa-miR-490-3p0.0014031.888625NAhsa-miR-342-3p0.0024342.136132PPP3R1, ZAK, BTN2A1, MRFAP1, ZIC4, RSBN1, FAM53C, PDGFRA, FUT8, UBE2D2hsa-miR-2210.0007132.181648CDKN1B, ATXN1, TMCC1, NSMCE4A, GOLSYN, EIF5A2, DCUN1D1, DMRT3, C12orf30, MIER3hsa-miR-1970.0011032.192276NAhsa-miR-19750.0034242.291544NAhsa-miR-125a-5p0.0025742.483418MCL1, SLITRK6, OSBPL9, ELOVL6, NIN, ALPK3, CGN, GTPBP2, CCNJ, SYVN1hsa-miR-142-5p0.0039222.625738BTBD7, RAB6B, FLJ10357, LRP1B, TRIM36, ALS2, EGLN3, CHD9, WDR26, SCOChsa-miR-135b3.37E-052.819987TSEN54, GGNBP2, C6orf106, NUCKS1, TMEM168, PELI2, LZTS1, NUDT4, HOXA10, ELOVL2hsa-miR-10a0.0011032.841119TBX5, NARG1, HOXA3, USP46, BACH2, RAP2A, SLC38A2, ANKFY1, NCOA6, BAZ2Bhsa-miR-2230.0020382.930734NFIA, FBXO8, STK39, SACS, RBM16, PDS5B, PHF20L1, CRIM1, FBXW7, SLC8A1hsa-miR-210.0019782.992536RP2, JAG1, SOX5, LEMD3, KIAA1012, BAHD1, ADNP, ASPN, CHD7, PELI1hsa-miR-1450.0011333.244704MDFIC, CACHD1, EPB41L5, SEMA6A, NUFIP2, SRGAP1, RIN2, CDC37L1, KIF21A, INOC1hsa-miR-199a-5p0.0070613.264147ATXN7, C11orf9, CELSR1, RAB10, CCNJ, CCNL1, SLC24A3, ZNF512B, ALS2, CCDC43hsa-miR-27a0.0034243.636233TMCC1, NXT2, HOXA10, DLL4, CCNJ, ANK1, SEMA6A, GPAM, OTX2, TEAD1

Overall Survival Analysis {#s0105}
-------------------------

We used OncoLnc to conduct overall survival analysis of ECT2, NR5A2, NRP2, and TGFBI in pancreatic cancer. We found that high mRNA expression of ECT2, NRP2, or TGFBI was associated with worse overall survival (log-rank *P* value = .001, .02, and .02, respectively; [Figure 4](#f0020){ref-type="fig"}, *A-D* and [Table 3](#t0015){ref-type="table"}). We also analyzed the predicted DEM regulators of the four DEGs and found that high expression of miR27a and miR21 was associated with worse overall survival (log-rank *P* values = .001 and .002, respectively; [Figure 4](#f0020){ref-type="fig"}, *E* and *F*). There was no significant association between miR302C expression and overall survival (data not shown). Then, we changed the percentage from 10% vs 90% to 20% vs 80%; the results also showed that high expression of ECT2, NRP2, or TGFBI was associated with worse overall survival ([Table 3](#t0015){ref-type="table"}). Finally, we also investigated associations between the DEGs and other kinds of cancer, including breast, lung, colorectal, and prostate cancer ([Table 5](#t0025){ref-type="table"}).Figure 4Prognostic value of four DEGs and their miRNA in pancreatic cancer patients. Prognostic value of (A) ETC2 (log-rank *P* value = .00124), (B) NR5A2 (log-rank *P* value = .139), (C) NRP2 (log-rank *P* value = .0177), (D) TGFBI (log-rank *P* value = .0199), (E) miR21 (log-rank *P* value = .00157), and (F) miR27a (log-rank *P* value = .00117).Figure 4Table 5Prognostic Value of Four DEGs in Other Kinds of Cancer PatientsTable 5Gene/Cancer NameECT2NR5A2NRP2TGFBIBreast cancer0.9560.2540.570.869Gastric cancer0.9830.7940.0910.00395Lung cancer0.04330.9650.9750.862Ovarian cancer0.1930.6220.9920.611Liver cancer0.002950.6140.007630.457

Expression of DEGs in Different Organs {#s0110}
--------------------------------------

We used " The Human Protein Atlas " to perform the basic expression level of DEGs in different human organs. We found that the basic expression of ECT2, NRP2, and TGFBI was at lower level than other organs with HPA dataset, GTEx dataset, and FANTOM5 dataset ([Figure 5](#f0025){ref-type="fig"}*A*, GTEx and FANTOM% not shown). We also analyzed the basic expression of DEGs in pancreas and cancer tissues with TCGA dataset. Those results showed that the expression of ECT2 and NRP2 was significant higher in pancreatic cancer tissues, but there was no significant difference in expression on TGFBI ([Figure 5](#f0025){ref-type="fig"}*B*). Furthermore, we found that NRP2 expression in pancreatic cancer is a big difference.Figure 5The basic expression of DEGs in different organs and cancer. The basic expression of DEGs in pancreas stood lower level in 37 kinds of organs (A). The expressions of ECT2 and NRP2 were significant higher in pancreatic cancer tissues (B).Figure 5

Expression of DEGs in Normal Pancreas and Pancreatic Cancer Cell Lines {#s0115}
----------------------------------------------------------------------

For further research of the different expression of DEGs in pancreatic cancer, we detected the protein expression between normal pancreas HDPE cell and different pancreatic cancer cell lines by Western blot. Those results showed that the protein expression of ECT2 in pancreatic cancer cell lines was higher than that in normal pancreas cell line. The expression of NRP2 was higher in some kinds of pancreatic cancer cell lines, such as ASPC1, PaCaDD119, PaCaDD137, and PaCaDD159, than normal pancreas cell line. There was higher expression level of TGFBI in normal pancreas cell line ([Figure 6](#f0030){ref-type="fig"}*A*). The q-PCR showed the same results with Western blot ([Figure 6](#f0030){ref-type="fig"}*B, C,* D). ECT2 was completely overexpressed in pancreatic cancer cell lines. NRP2 and TGFBI were partly overexpressed and obviously not overexpressed, respectively, in pancreatic cancer cell lines.Figure 6The basic expression of DEGs in normal pancreas and pancreatic cancer cell lines. The protein expression of DEGs in normal pancreas and pancreatic cancer cell lines (A). The mRNA expression of DEGs in normal pancreas and pancreatic cancer cell lines (B, C, D). \**P* value \< .05.Figure 6

CRISPR/Cas9 Gene Editing {#s0120}
------------------------

We detected ECT2 function to verify the data mining results. From the basic expression of different pancreatic cancer cell lines and normal pancreas cell line, we found that there was higher expression of ECT2 in MiaPaCa2 cell line. Then, we used Crispr Cas9 gene editing system to knockout ECT2 in MiaPaCa2 cells ([Figure 7](#f0035){ref-type="fig"}*A*). We detected the proliferation ability with ECT2 knocked out cells, negative control cells, and wild-type cells. Those results showed that ECT2 knocked out cells grew slower than negative control and wild-type cells ([Figure 7](#f0035){ref-type="fig"}*B*). Furthermore, we also detected the migration ability with ECT2 knocked out cells. Those results showed that the migration ability of ECT2 knocked out cells was lower than negative control and wild-type cells ([Figure 7](#f0035){ref-type="fig"}, *C* and *D*).Figure 7Knockout of ECT2 decreased proliferation and migration ability in MiaPaCa2 cells. Knockout of ECT2 by Crispr Cas9 gene editing system inhibited protein expression of ECT2 in MiaPaCa2 cells (A). ECT2 knocked out cells grew slower than control groups (B). ECT2 knocked out cells migration slower than control groups (C and D). \**P* value \< .05.Figure 7

Discussion {#s0125}
==========

Pancreatic cancer is a nearly universally fatal disease and is one of the few cancer types that continue to increase in incidence [@bb0165]. It is expected to become the second leading cause of cancer-related deaths in the United States in the next few years. Peak incidence of pancreatic cancer has been linked to few predisposing factors, including cigarette smoking, red meat, obesity, and heavy alcohol consumption along with pancreatic disease [@bb0170], [@bb0175], [@bb0180]. Because of its aggressive behavior and frequently late diagnosis, research aiming at early diagnosis of pancreatic cancer or its precursors is crucial. Molecular biomarkers play an important role in early diagnosis, and the rapid development of high-throughput technologies has resulted in an increasing number of biomarkers being screened for disease progression [@bb0185], [@bb0190]. Biomarkers enable the identification of genes, miRNAs, LncRNAs, and so on for early diagnosis, treatment, and prognosis of the disease, including pancreatic cancer. In particular, microarray and follow-up experiments performed in our laboratory over the last few years [@bb0195], [@bb0200] have shown that we can identify biomarkers and key genes in pancreatic cancer [@bb0195], [@bb0205].

In this study, we used three mRNA and one miRNA expression microarray datasets to identify biomarkers in pancreatic cancer. The four expression microarrays correspond to two different platforms, making the screen result more robust. We performed a comprehensive analysis of the DEMs, including functional and pathway enrichment analysis, and PPI analysis. Next, we screened the DEGs among the putative targets of the DEMs. Compared to previous studies [@bb0075], [@bb0210], [@bb0215], the samples included were more comprehensive and random. We identified a total of 236 DEGs among the three mRNA expression microarray datasets, consisting of 182 up-and 54 downregulated genes. Upregulated DEGs were mainly associated with the integrin-mediated signaling pathway, proteolysis, and the PI3K-Akt signaling pathway, which have been proved to have a close relationship with pancreatic cancer [@bb0220]. Twelve of the 236 DEGs were highly connected in the PPI network and were in the core of the PPI network. Such hub genes are usually the focus of microarray-based biomarker research. Indeed, an overall survival analysis with the clinical data from TCGA showed the expected trend, with 10 of these genes being strongly associated with overall survival in pancreatic adenocarcinoma. However, the correlation between increased overall survival and low expression levels is only strong for the bottom 10%, and the number of hub genes displaying a significant correlation decreases to 5 or 4 when then 20th and 40th percentiles are considered. In addition, we identified 21 DEMs and their more than 500 predicted target genes. In order to improve the generalizability and robustness of the predictions, DEM target predictions were obtained with an ensemble approach [@bb0150]. Four DEM targets were also DEGs: ECT2 (miR302c), NR5A2 (miR27a), NRP2 (miR27a and miR331-3p), and TGFBI (miR21). All four DEGs were upregulated in pancreatic cancer tissue. miRNA including miR27a, miR331-3p, and miR21 were upregulated; miR302c was downregulated. NR5A2 has been reported to be upregulated in pancreatic cancer [@bb0225]; ECT2, NRP2, and TGFBI are novel candidates. Overall survival analysis of these genes showed that upregulation of ECT2, NRP2, or TGFBI is significantly correlated with poor survival of pancreatic cancer patients. Interestingly, 7 patients had low expression levels for ECT2, NRP2, and TGFBI, and 13 patients had low expression levels for 2 of these 3 genes. However, this finding warrants further investigation.

ECT2 locates at 3q26.31, is a BRCT-containing guanidine exchange factor for Rho GTPases, and was found to be a responder to DNA damage [@bb0230]. It controls cell division and exerts oncogenic functions in multiple cancers [@bb0235], [@bb0240]. Patients with high expression of ECT2 also have poor overall survivals in lung (log-rank *P* value = .04) and liver (log-rank *P* value = .003) cancer. Additionally, ECT2 has been reported to play an important role in the Wingless/Wnt and KRAS signaling pathways [@bb0245], [@bb0250]. The KRAS is a key signaling pathway in pancreatic cancer. Typical alterations in the molecular signaling include mutations in KRAS in 95% of pancreatic cancer [@bb0205], [@bb0255]. Consistent with our results, previous studies have also shown that ECT2 is an oncogene which is overexpressed in pancreatic tumor tissues [@bb0260]. However, the oncogenic mechanism for pancreatic cancer has rarely been explored. NRP2 is located at 2q33.3; is a nontyrosine kinase receptor frequently overexpressed in various malignancies; and may play a role in cardiovascular development, axon guidance, and tumorigenesis [@bb0265]. Some studies have shown that it is required for maintaining endocytic activity in cancer cells, which supports their oncogenic activities and confers drug resistance [@bb0270]. Further, it has been suggested that NRP2 works its biological function via the GSK3β and VEGFC/VEGFR3 signaling pathway [@bb0275], [@bb0280], and GSK3β plays a key role in resistance to pancreatic cancer therapy [@bb0285]. We performed overall survival analysis of NRP2 in some common tumors and found that upregulated NRP2 is significantly correlated with poor overall survival of liver (log-rank *P* value = .008) tumor patients. In our study, NRP2 we could not confirm a significant correlation of NRP2 expression and survival in breast and gastric cancer, but other studies have shown a function in breast and gastric tumor, proving that it is an important gene in solid tumors [@bb0290], [@bb0295]. However, there is no study focused on NRP2 function in pancreatic cancer. Finally, TGFBI, also known as βig-H3, is a protein inducible by TGFβ1 and secreted by many cell types [@bb0300]. Furthermore, TGFBI is an important component of the Wnt signaling pathway [@bb0305]. It is located at 5q31.1. In our study, the patients with upregulated TGFBI have poor survival rate in gastric (log-rank *P* value = .004) and pancreatic (log-rank *P* value = 2.0 × 10^−2^) cancer. TGFBI has been studied in the context of many different diseases, but no study has revealed its function and mechanism in pancreatic cancer. Interestingly, all ECT2, NRP2, and TGFß1 are involved in the Wnt signaling pathway, which has been reported to be an important regulated part and potential treatment target in pancreatic cancer in multiple studies. These observations support our hypothesis that ECT2, NRP2, and TGFBI are potential regulated components of pancreatic cancer and that there may be more interactions among them. Together with NR5A2, these four genes grant further *in vivo* and *in vitro* study.

Among the 21 DEMs in pancreatic cancer, we identified 19 upregulated and 2 downregulated miRNAs. miR27a was the strongest upregulated miRNA, and miR630 was the strongest downregulated miRNA. Some studies have reported that miR27a is a cooperative repressor of a network of tumor suppressor genes, and inhibition of miR27a has been shown to have synergistic effects in reducing proliferation of PDAC cells in culture and growth of xenograft tumors in mice [@bb0110]. NR5A2 and NRP2 are the predicted targets of miR27a, and ECT2, NR5A2, NRP2, and TGFBI were DEGs in the three mRNA expression datasets. miR21, miR302c, and miR331-3p potentially play a role in pancreatic cancer.

We also checked the basic expression of DEGs in different organ. We found that the basic expression of ECT2, NRP2, and TGFBI was at a lower level than other organs with HPA dataset, GTEx dataset, and FANTOM5 dataset. In HPA dataset, those 3 DEGs were the last one of 37 organs. However, in the comparison of expression between pancreas and pancreatic cancers from TCGA, we can that found ECT2 and NRP2 were statistically significantly higher in cancer tissues. It predicted that the higher expression of ECT2 and NRP2 may play a role in tumorigenicity of pancreatic cancer.

For further verification of above data-mining results, we used basic biology experiment to detect the basic expression of ECT2, NRP2, and TGFBI in normal pancreas cell line and pancreatic cancer cell lines. Those results proved that ECT2 and NRP2 had higher expression level in pancreatic cancer. However, there was higher expression level of TGFBI in normal pancreas cell line. Globally expressed ECT2 was associated with worse overall survival stably. Mixed expressed NRP2 was associated with worse overall survival based on the percentiles of expression values and cancer kinds. Outlier expressed TGFBI was associated with worse overall survival occasionally ([Table 3](#t0015){ref-type="table"}, [Table 5](#t0025){ref-type="table"}). We think ECT2 and NRP2 may play an important role in pancreatic cancer.

Furthermore, we also did gene function analysis by experiment. We made MiaPaCa2 ECT2 knockout stable cell lines to verify the above results with Crispr Cas9 system. As those results showed, knockout of ECT2 decreased the proliferation and migration ability of MiaPaCa2 cells. It predicted that ECT2 was an important gene in pancreatic cancer. This is in line with expectations based on above results.

This study is a next step in identifying relevant biomarkers for early diagnosis and progression of pancreatic cancer. In this study, we combined high-throughput mRNA and miRNA expression datasets with functional and regulatory network analyses to screen for biomarkers. miR21, miR27a, miR302c, and miR331-3p and their predicted targets genes ECT2, NRP2, and TGFBI were selected as promising candidates. Then, we detected the basic expression level of DEGs in various organ tissues and different pancreatic cancer with data mining and experiment methods. Those showed that ECT2 and NRP2 were in line with data mining results. We also used Cripsr Cas9 gene editing system to knockout ECT2 and proved its important function in pancreatic cancer. Meanwhile, we will continue to research ECT2 and NRP2 functions and mechanisms in pancreatic cancer and assess their clinical application prospects. We believe that ECT2 and NRP2 can play as potential biomarker in pancreatic cancer patients, and they may be potential target therapy site with Crispr Cas9 gene editing system for pancreatic cancer.
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[^1]: If the \|Log FC\| \> 1, and Adj *P* \< .05, it means that the gene has more than 10-fold change between pancreatic cancer and normal tissue, and the difference is statistically significant. The adjusted *P* values are listed in the Adj *P* value column of the results table. The Benjamini & Hochberg false discovery rate method is selected by default in GEO as it is the most commonly used adjustment for microarray data and provides a good balance between discovery of statistically significant genes and limitation of false positives.
